The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an ...

The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted ...

Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...

With many patients utilizing medical cannabis, it is important for nurses to be aware of potential drug-drug interactions, an ...

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...

Topical treatments may help ease chemotherapy-induced peripheral neuropathy, but more research is needed. Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients ...

Mirdametinib led to confirmed responses and meaningful pain and health-related quality of life improvements in both children and adults with neurofibromatosis type 1-associated PNs.

The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...

At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell ...

Anitocabtagene autoleucel may be a promising CAR-T cell therapy option for patients with relapsed/refractory myeloma.